# COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer

> **NCT03898895** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 36 (estimated)

## Conditions studied

- Biliary Tract Cancer
- Radiotherapy
- Immunotherapy

## Interventions

- **COMBINATION_PRODUCT:** Radiotherapy+anti-PD-1 antibody

## Key facts

- **NCT ID:** NCT03898895
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-10
- **Primary completion:** 2024-11
- **Final completion:** 2024-11
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03898895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03898895, "COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT03898895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*